NCT05428358 Incremental Value of Magnetic Resonance Imaging in Selection of Pancreatic Cancer Patients for Surgery
| NCT ID | NCT05428358 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Aarhus |
| Condition | Pancreatic Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 200 participants |
| Start Date | 2022-08-30 |
| Primary Completion | 2027-12-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 200 participants in total. It began in 2022-08-30 with a primary completion date of 2027-12-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The aim of the study is to examine the incremental value of using magnetic resonance imaging (MRI) in addition to computed tomography (CT) in the diagnostic workup of pancreatic cancer patients.
Eligibility Criteria
Inclusion criteria: * Pancreatic cancer patients considered to have a locally resectable or borderline resectable tumor by the local hepato-pancreato-biliary multidisciplinary team board * No liver metastases on CT * At least 18 years old and able to provide informed consent * Expected pancreatic ductal adenocarcinoma based on CT scan Exclusion criteria: * Metastatic disease * Prior receipt of neoadjuvant chemotherapy or downstaging/-sizing treatment * Comorbidity rendering major surgery unfeasible (inoperable) * No informed consent * Unable to undergo MRI (Kidney insufficiency (eGFR \< 60 ml/min/1.73 m2 body surface ar-ea); Claustrophobia; Cardiac pacemaker) * Postoperative histology other than adenocarcinoma of pancreato-biliary origin. * MRI with liver-specific contrast performed during standard workup.
Contact & Investigator
Frank Mortensen, MD, DMSc
STUDY CHAIR
Aarhus University Hospital
Frequently Asked Questions
Who can join the NCT05428358 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 99 Years, studying Pancreatic Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05428358 currently recruiting?
Yes, NCT05428358 is actively recruiting participants. Contact the research team at jakob.kirkegaard@auh.rm.dk for enrollment information.
Where is the NCT05428358 trial being conducted?
This trial is being conducted at Aalborg, Denmark, Aarhus, Denmark, Copenhagen, Denmark.
Who is sponsoring the NCT05428358 clinical trial?
NCT05428358 is sponsored by University of Aarhus. The principal investigator is Frank Mortensen, MD, DMSc at Aarhus University Hospital. The trial plans to enroll 200 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.